Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755842 | 0.90 | SRD5A1 (0.47) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL12410677 | 0.86 | HPGD (0.48) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL17462699 | 0.86 | MMP13 (0.49) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL12421900 | 0.85 | HPGD (0.50) | SMN1; SMN2KMT2AMEN1GLAHPGD | |
| SCHEMBL18724614 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHPGDTP53 | |
| SCHEMBL19596853 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL12414355 | 0.83 | CA1 (0.39) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL14753641 | 0.83 | POLB (0.50) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL18079677 | 0.82 | KMT2A (0.45) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL11955698 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ANPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-07-26 | — | — | US | disclosed |
| US-9999657-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-03-29 | — | — | US | disclosed |
| US-9861705-B2 | Conjugates of an IL-2 moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2018-01-09 | — | — | US | disclosed |
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SMN1; SMN2 3568/4885KMT2A 1613/4885NPC1 3345/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SMN1; SMN2 1435/4885KMT2A 1159/4885NPC1 2429/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SMN1; SMN2 2365/4885KMT2A 2002/4885NPC1 2217/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SMN1; SMN2 2381/4885KMT2A 2142/4885NPC1 1972/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 2077/4885KMT2A 4160/4885NPC1 3081/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 1898/4885KMT2A 4093/4885NPC1 3291/4885 |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | IL2, IL2RA, ILF2 | SMN1; SMN2 3179/4885KMT2A 797/4885NPC1 3257/4885 |
| US-20180207286-A1 | CONJUGATES OF A CHOLINESTERASE MOIETY AND A POLYMER | BCHE, ACHE, DNPEP | SMN1; SMN2 916/4885KMT2A 896/4885NPC1 1164/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | SMN1; SMN2 1544/4885KMT2A 1868/4885NPC1 1759/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | SMN1; SMN2 3529/4885KMT2A 1218/4885NPC1 2946/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | SMN1; SMN2 4077/4885KMT2A 3473/4885NPC1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.